TGFB1 and ovarian carcinoma: Therefore, we assessed the relative protein expression of TGFBI and SPARC and found that both were expressed at variable levels in a panel of ovarian cancer cell lines and in the normal, immortalized Met5A mesothelial cell line both before and after transforming growth factor beta1 (TGFß1) treatment (Fig 1A).